HomeCompareTBIO vs ARCC

TBIO vs ARCC: Dividend Comparison 2026

TBIO yields 3921.57% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBIO wins by $5928317923792.10M in total portfolio value
10 years
TBIO
TBIO
● Live price
3921.57%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5928317923792.13M
Annual income
$5,645,144,171,791,441,000.00
Full TBIO calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — TBIO vs ARCC

📍 TBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBIOARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBIO + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBIO pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBIO
Annual income on $10K today (after 15% tax)
$333,333.33/yr
After 10yr DRIP, annual income (after tax)
$4,798,372,546,022,725,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, TBIO beats the other by $4,798,372,546,022,725,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBIO + ARCC for your $10,000?

TBIO: 50%ARCC: 50%
100% ARCC50/50100% TBIO
Portfolio after 10yr
$2964158961896.08M
Annual income
$2,822,572,085,895,720,400.00/yr
Blended yield
95.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

TBIO
Analyst Ratings
8
Buy
6
Hold
Consensus: Buy
Altman Z
-15.6
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBIO buys
0
ARCC buys
0
No recent congressional trades found for TBIO or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBIOARCC
Forward yield3921.57%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$5928317923792.13M$24.5K
Annual income after 10y$5,645,144,171,791,441,000.00$1.16
Total dividends collected$5908985646403.93M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: TBIO vs ARCC ($10,000, DRIP)

YearTBIO PortfolioTBIO Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$402,857$392,156.86$11,381$541.15+$391.5KTBIO
2$15,195,831$14,764,774.15$12,621$284.08+$15.18MTBIO
3$536,754,727$520,495,188.22$13,827$145.31+$536.74MTBIO
4$17,756,748,906$17,182,421,348.17$15,062$73.43+$17756.73MTBIO
5$550,236,533,968$531,236,812,638.47$16,364$36.89+$550236.52MTBIO
6$15,973,499,921,404$15,384,746,830,057.32$17,757$18.49+$15973499.90MTBIO
7$434,496,251,181,035$417,404,606,265,133.20$19,258$9.25+$434496251.16MTBIO
8$11,075,986,607,305,350$10,611,075,618,541,642.00$20,880$4.63+$11075986607.28MTBIO
9$264,648,366,355,783,070$252,797,060,685,966,340.00$22,636$2.32+$264648366355.76MTBIO
10$5,928,317,923,792,128,000$5,645,144,171,791,441,000.00$24,539$1.16+$5928317923792.10MTBIO

TBIO vs ARCC: Complete Analysis 2026

TBIOStock

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Full TBIO Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this TBIO vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBIO vs SCHDTBIO vs JEPITBIO vs OTBIO vs KOTBIO vs MAINTBIO vs HTGCTBIO vs GBDCTBIO vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.